Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NEURONTIN vs KHAPZORY
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Gabapentin binds to the α2δ subunit of voltage-gated calcium channels, inhibiting calcium influx and reducing neurotransmitter release, particularly glutamate, norepinephrine, and substance P. It does not interact with GABA receptors.
Lefamulin, a pleuromutilin antibiotic, inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, specifically to the peptidyl transferase center (PTC) at the A-site cleft, thereby blocking peptide bond formation and protein translation.
Postherpetic neuralgia,Partial onset seizures (adjunctive therapy),Restless legs syndrome (off-label),Neuropathic pain (off-label),Diabetic peripheral neuropathy (off-label),Fibromyalgia (off-label),Generalized anxiety disorder (off-label)
Community-acquired bacterial pneumonia (CABP) in adults,Off-label: None established
300 mg orally once daily on day 1, 300 mg twice daily on day 2, then 300 mg three times daily on day 3; titrate up to effective dose, usual maintenance 300-600 mg three times daily, maximum 3600 mg/day.
KHAPZORY (lenalidomide) 25 mg orally once daily on days 1-21 of repeated 28-day cycles.
Terminal elimination half-life is 5–7 hours in patients with normal renal function; in elderly or those with renal impairment, half-life may be prolonged up to 132 hours; requires dose adjustment for creatinine clearance <60 m L/min.
Terminal elimination half-life: 15-20 hours; clinical context: supports once-daily dosing
Gabapentin does not undergo hepatic metabolism; it is excreted unchanged in urine. No involvement of cytochrome P450 enzymes.
Primarily metabolized by cytochrome P450 3A4 (CYP3A4) and to a lesser extent by CYP2D6 and CYP2C8; also undergoes conjugation and oxidation.
Renal elimination as unchanged drug: >90%; 0.3% is excreted in feces; biliary elimination is negligible.
Renal: 90% as unchanged drug; fecal: <5% as metabolites
<3% bound to plasma proteins (negligible).
90-95% bound to albumin
Volume of distribution is 0.8 L/kg (57 L in a 70 kg adult), indicating distribution into total body water.
0.3-0.4 L/kg; clinical meaning: distributes primarily into extracellular fluid
Oral bioavailability is approximately 60% (30–90% with interindividual variability); decreases with higher doses due to saturable absorption; not affected by food.
Oral: 70-85%
For Cr Cl 30-59 m L/min: 200-700 mg twice daily. For Cr Cl 15-29 m L/min: 200-700 mg once daily. For Cr Cl <15 m L/min: 100-300 mg once daily. Hemodialysis: loading dose 300-400 mg, then 200-300 mg after each 4-hour dialysis session.
Cr Cl ≥60 m L/min: 25 mg daily. Cr Cl 30-60 m L/min: 10 mg daily. Cr Cl <30 m L/min (not requiring dialysis): 15 mg every 48 hours. Cr Cl <30 m L/min (requiring dialysis): 5 mg once daily; on dialysis days, administer after dialysis.
No specific dose adjustment guidelines; pharmacokinetics unchanged in hepatic impairment per manufacturer.
Child-Pugh Class A: No adjustment. Child-Pugh Class B: Initiate at 10 mg daily. Child-Pugh Class C: Initiate at 5 mg daily; may titrate based on tolerance.
For epilepsy (ages 3-12): initial 10-15 mg/kg/day in 3 divided doses, titrate over 3 days to effective dose, maintenance 25-35 mg/kg/day in 3 divided doses; maximum 50 mg/kg/day. For postherpetic neuralgia: not indicated.
Safety and efficacy not established for patients <18 years; no recommended dosing.
Initiate at lower dose (e.g., 100-300 mg/day) and titrate slowly; monitor for dizziness, sedation, and renal function; adjust dose based on creatinine clearance.
No specific dose adjustment based on age alone; adjust for renal function as per renal adjustment guidelines; monitor for myelosuppression, thromboembolic events, and peripheral neuropathy more frequently.
None.
None
Respiratory depression: risk increased with opioid coadministration or in elderly patients,Central nervous system effects: dizziness, somnolence, ataxia,Increased seizure frequency with abrupt withdrawal,Suicidal behavior and ideation,Anaphylaxis and angioedema,Drug reaction with eosinophilia and systemic symptoms (DRESS),Pancreatitis,Abrupt discontinuation may precipitate status epilepticus in patients with seizures
QTc interval prolongation (avoid in patients with known QTc prolongation, electrolyte disturbances, or concurrent use of QTc-prolonging agents),Hepatotoxicity (monitor liver function tests; discontinue if signs of liver injury occur),Clostridioides difficile-associated diarrhea (CDAD),Hypersensitivity reactions including anaphylaxis,Avoid use in patients with moderate to severe hepatic impairment (Child-Pugh B or C)
Hypersensitivity to gabapentin or any component of the formulation
Hypersensitivity to lefamulin or any component of the formulation,Concurrent use with strong CYP3A4 inducers (e.g., rifampin, carbamazepine, phenytoin) reduces lefamulin exposure; avoid coadministration
No significant food interactions. Avoid alcohol due to additive CNS depression.
No significant food interactions known. Avoid alcohol as it may increase risk of methotrexate toxicity.
First trimester: Increased risk of major congenital malformations (e.g., neural tube defects, heart defects) based on epidemiological data; avoid use if possible. Second and third trimester: Risk of fetal growth restriction, preterm birth, and neonatal withdrawal symptoms (e.g., feeding difficulties, irritability) after in utero exposure.
KHAPZORY (levonorgestrel) is a progestin-only emergency contraceptive. Limited human data; no increased risk of major birth defects in case of inadvertent use during pregnancy. Theoretically, no known teratogenic effect in any trimester.
Gabapentin is excreted into human milk; M/P ratio approximately 1.0. Limited data suggest low infant exposure (relative infant dose <2% of maternal weight-adjusted dose). Monitor infant for drowsiness, poor feeding, and gastrointestinal disturbances. Benefit of breastfeeding should be weighed against potential risks.
Levonorgestrel is excreted into human milk; estimated infant dose < 1% of maternal dose. M/P ratio not reported. Generally considered compatible with breastfeeding.
Increased clearance of gabapentin during pregnancy may require dose adjustments. Monitoring of clinical response and adverse effects is recommended. Consider gradual dose reduction postpartum to pre-pregnancy levels. No established dosing guidelines; individualize based on therapeutic response and tolerability.
Not indicated for use during pregnancy. No dose adjustment applicable.
Titrate slowly to reduce CNS depression risk. Reduce dose in renal impairment (Cr Cl <60). Drug of choice for postherpetic neuralgia. Gabapentin is not effective for acute pain. Avoid abrupt discontinuation to prevent withdrawal. Use with caution with opioids due to respiratory depression risk.
KHAPZORY (levoleucovorin) is used as a rescue agent after high-dose methotrexate therapy to prevent severe toxicity. Monitor serum methotrexate levels closely; administer leucovorin until methotrexate level is <5×10^-8 M. Adjust dose in renal impairment. Not interchangeable with folic acid.
May cause dizziness and drowsiness; avoid driving until effects known.,Take with or without food; avoid alcohol.,Do not stop suddenly; taper under doctor guidance.,May take time to work; adhere to prescribed dosing schedule.,Report any signs of allergic reaction, mood changes, or suicidal thoughts.
Take this medication exactly as prescribed, usually every 6 hours for a set number of doses.,Do not skip doses, as this may increase the risk of methotrexate toxicity.,Inform your doctor if you experience shortness of breath, rash, or signs of allergic reaction.,Keep all appointments for blood tests to monitor methotrexate levels.,Avoid taking folic acid supplements unless directed by your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NEURONTIN vs KHAPZORY, answered by our medical review team.
NEURONTIN is a Antiepileptic that works by Gabapentin binds to the α2δ subunit of voltage-gated calcium channels, inhibiting calcium influx and reducing neurotransmitter release, particularly glutamate, norepinephrine, and substance P. It does not interact with GABA receptors.. KHAPZORY is a Antiepileptic that works by Lefamulin, a pleuromutilin antibiotic, inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, specifically to the peptidyl transferase center (PTC) at the A-site cleft, thereby blocking peptide bond formation and protein translation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NEURONTIN and KHAPZORY depend on the specific clinical indication. These are both Antiepileptic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NEURONTIN is: 300 mg orally once daily on day 1, 300 mg twice daily on day 2, then 300 mg three times daily on day 3; titrate up to effective dose, usual maintenance 300-600 mg three times daily, maximum 3600 mg/day.. The standard adult dose of KHAPZORY is: KHAPZORY (lenalidomide) 25 mg orally once daily on days 1-21 of repeated 28-day cycles.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NEURONTIN and KHAPZORY in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NEURONTIN is classified as Category C. First trimester: Increased risk of major congenital malformations (e.g., neural tube defects, heart defects) based on epidemiological data; avoid use if possible. Second and third . KHAPZORY is classified as Category C. KHAPZORY (levonorgestrel) is a progestin-only emergency contraceptive. Limited human data; no increased risk of major birth defects in case of inadvertent use during pregnancy. The. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.